Biotech

The Chief Medical Officer (CMO) Summit is the only industry event focusing on the unique needs of CMOs at small and emerging Biotechs.  These executives are responsible for both clinical trials and business; their role is very different from the traditional CMOs at larger Biotechs or Pharma companies.  The conference offers a distinct forum for CMOs to discuss the challenges they face, and share best practices and solutions.  

CRAACO is the only program to address how to connect clinical research to clinical care and what it takes to integrate both for better access.  The conference is designed to bring together all of the stakeholders from Pharma companies, Biotechs and CROs, as well as hospital and healthcare systems and physician groups to discuss how this has been done, some of the challenges, and explore the strategies, partnerships, and tools to achieve it.

The leading clinical trial supply conference in East Asia with a focus on providing delegates with practical take-aways and solutions to their most current operational and outsourcing challenges in clinical trials. This event focuses on the regional pharmaceutical business in Asia, highlighting the industry’s current difficulties as well as its exciting innovations and growth prospects.

This is the unmissable event that the pharmaceutical, biotechnology, and medical device communities need to come together and discuss strategies for operational success in clinical trials. Combining our OCT, CTS and Medical Devices events, this is the perfect platform for professionals from across a range of clinical trial functions to meet, network, and hear about latest developments.

The largest neutral healthcare conference in Europe for life sciences professionals to address the hottest challenges. As the knowledge and innovation hub uniting science, healthcare, patients and regulatory professionals, DIA Europe commits to transforming insights into action by bridging the gap between critical policy discussions and real-world expertise. 

The LSX Nordic Congress is the leading senior executive strategy, investment and partnering conference for the Nordic region. It has been connecting life science and healthcare industry leaders with international investment and strategic partners to further the growth, development and internationalisation of Nordic life science and healthcare innovation since 2018.

DiscoverBMB is the annual meeting of the American Society for Biochemistry and Molecular Biology. With a mission to share the latest, most impactful research findings in the molecular life sciences, DiscoverBMB offers an exciting agenda that includes talks by the field’s foremost experts, interactive workshops on the latest trends, technologies and techniques, and an invigorating exhibition of posters, services and products. The meeting attracts researchers in academia and industry, educators, trainees and students from across the globe. It offers unparalleled opportunities for collaborating, networking and recruiting.

Where thousands of chemistry professionals meet to share ideas and advance scientific and technical knowledge.

With systemic toxicity challenges plaguing the AAV field, low-dose CNS indications are an ideal target for gene therapy. The plethora of neurological indications dominating gene therapy pipelines vary from rare neurological disorders to more common diseases including Parkinson’s, epilepsy and neurodevelopmental disorders. As programs advance globally, the 3rd Annual Gene Therapy for Neurological Disorders Europe meeting is the field’s definitive forum to showcase the European landscape’s progress and specific regulatory challenges. Gene therapy developers from all of the world, including Europe’s brightest minds in CNS gene therapy, will unite in Paris to share their research progress and host an industry-dedicated discussion.

In the context of unprecedented gene therapy investment and clinical progress, with mounting regulatory scrutiny, Gene Therapy Analytical Development Europe will unite innovative biotech and pharma organisations to develop robust analytical tools to guarantee the consistency, quality, and safety of gene therapy products Whether you’re looking for specific characterisation, potency or infectivity approaches to improve your current analytical toolbox or if you’re seeking to understand how gene therapy analytics differ from other biologics you’ve worked on in the past, this focused, technical event will provide insights specifically on the unique analytical challenges posed by gene therapy vectors, delivered by ‘boots on the ground’ scientists grappling with these challenges first-hand. Join 150+ analytical pioneers to discover the realities of working with tools like dPCR, AUC and HPLC, as well as how and where these tools can be most effective in process development, and what the European regulators expect in order to grant approval. Whether you’re working with AAV or lentiviral vectors, this is your opportunity to enhance your existing analytical methods and explore innovative new tools to support safe and effective gene therapy development.